This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Jazz Pharmaceuticals’s 8K filing here.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
See Also
- Five stocks we like better than Jazz Pharmaceuticals
- Breakout Stocks: What They Are and How to Identify Them
- Tesla Investors Continue to Profit From the Trump Trade
- Using the MarketBeat Stock Split Calculator
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- What Do S&P 500 Stocks Tell Investors About the Market?
- Netflix Ventures Into Live Sports, Driving Stock Momentum
